Efficacy of praziquantel has been maintained over four decades (from 1977 to 2018): A systematic review and meta-analysis of factors influence its efficacy

Abstract

Background The antihelminthic drug praziquantel has been used as the drug of choice for treating schistosome infection for more than 40 years. Although some epidemiological studies have reported low praziquantel efficacy in cure rate (CR) and/or egg reduction rate (ERR), there is no consistent robust evidence of the development of schistosome resistance to praziquantel (PZQ). There is need to determine factors that lead to variable treatment CR and/or ERR. Therefore, we conducted a systematic review and meta-analysis to review CR and ERR as well as identify their predictors. Methodology/Principal findings In this systematic review and meta-analysis, a literature review was conducted using Biosis Citation Index, Data Citation Index, MEDLINE, and Web of Science Core Collection all of which were provided through Web of Science. Alongside these, EMBASE, and CAB abstracts were searched to identify relevant articles. Random effect meta-regression models were used to identify the factors that influence CR and/or ERR by considering differences in host characteristics and drug dose. In total, 12,127 potential articles were screened and 146 eligible articles (published from 1979 to 2020) were identified and included for the meta-analysis. We found that there has been no significant reduction in CR or ERR over the study period. The results showed more variability in CR, compared with ERR which was more consistent and remained high. The results showed a positive effect of “PZQ treatment dose” with the current recommended dose of 40 mg/kg body weight achieving 57% to 88% CR depending on schistosome species, age of participants, and number of parasitological samples used for diagnosis, and ERR of 95%. Conclusions/Significance Based on a review of over 40 years of research there is no evidence to support concerns about schistosomes developing resistance to PZQ. These results indicate that PZQ remains effective in treating schistosomiasis.

Improving anthelmintic treatment for schistosomiasis and soil-transmitted helminthiases through sharing and reuse of individual participant data

“…Notwithstanding these reports—and although resistance to praziquantel can be induced in the laboratory—and can emerge in natural populations 30 , there remains no conclusive evidence for its establishment in the field and the topic remains controversial 25 , 33 , 34 . Moreover, a recent meta-analysis found that the efficacy of praziquantel has been maintained since its introduction as the preferred treatment for SCH in the late 1970s 35 .…”

“…Praziquantel is used exclusively for PC regimens against SCH, typically given at a dose of 40 mg/kg. Some (but not all 47 ) studies have shown 60 mg/kg (typically divided into three 20 mg/kg doses given over the course of a single day) to be more efficacious than the single 40 mg/kg dose 19 , 35 , 48 , 49 . There also exists evidence that repeated doses of praziquantel may improve responses 50 and that co-administration of food increases bioavailability 51 , 52 , which is increasingly recommended as best practice in MDA.…”

Identification of novel modulators of a schistosome transient receptor potential channel targeted by praziquantel

“…Schistosomiasis, as well as several other parasitic flatworm infections [ 2 ], are treated using the anthelmintic drug praziquantel (PZQ). PZQ has remained an effective treatment for schistosomiasis over four decades of clinical use [ 3 ], underpinning recent mass drug administration (MDA) campaigns aimed at decreasing infections and morbidity in vulnerable populations. Alternatives to PZQ are however needed.…”

Fulminant Hepatitis and Ulcerative Colitis: Case Report of Ethiopian Child with Schistosomiasis and Amebiasis Co-Infection

“…The immunologic character of the glomerular lesion in S. mansoni is one of the postulated mechanisms. 7 , 13 , 15 , 22 , 38–40 …”